KOSDAQBiotech & Pharma042520

Hans Biomed

₩12,390▲ 0.57%2026-11-18 close
Market Cap
₩176.7B
Turnover
₩900M
Volume
70K
Shares out.
14.3M
PER
—
PBR
—
EPS
-₩1,557
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Skin booster growth drives profit recovery; litigation and balance sheet are the swing factors

Hans Biomed's quarterly revenue has risen for four consecutive quarters from the third quarter of 2025 through the second quarter of 2026, driven by its CellREDM skin booster and skin graft products, but the large loss in the year ended September 2025 and a debt ratio of 273.0% remain financial challenges.

  1. 1

    Q2 2026 revenue was KRW 36.3 billion, up 65.0% year on year, and operating profit of KRW 4.1 billion has stayed positive since the fourth quarter of 2025, when the company returned to profit.

  2. 2

    CellREDM reached KRW 15.4 billion in cumulative sales for the first three quarters of fiscal 2026 (October 2025 to June 2026), and third-quarter sales rose 62% from the prior quarter, according to the company's August 2026 announcement.

  3. 3

    The year ended September 2025 posted an operating loss of KRW 25.9 billion and a net loss attributable to controlling shareholders of KRW 31.3 billion, extending a run of losses that began in the year ended September 2023.

  4. 4

    Total liabilities were KRW 92.5 billion at the end of September 2025, and the debt ratio rose to 273.0% from 81.3% a year earlier.

  5. 5

    In November 2025, about KRW 22 billion was paid to roughly 5,300 participants in the first BellaGel breast implant lawsuit, and the possibility of further suits remains an uncertainty.

02

Business structure

Hans Biomed is a bio-medical device company whose core business is implant materials made from human tissue. In the first three quarters of fiscal 2026 (October 2025 to June 2026), skin graft products generated cumulative revenue of KRW 48.5 billion, up 157% year on year, and their share of total revenue rose to 48%.

The skin graft line consists of the ECM-based skin booster CellREDM, the sheet-type BellaCellHD and the powder-type BellaGen Plus.

CellREDM, launched in September 2025, reached KRW 15.4 billion in cumulative sales over the same nine months, and third-quarter sales of KRW 7.2 billion were 62% above the prior quarter, making up 20% of the quarter's total.

Bone graft cumulative revenue was KRW 24.8 billion, up 25%, and sales of orthopedic bone graft products to China began in January 2026.

According to Yuanta Securities, revenue in the year ended September 2025 was made up of skin graft products of KRW 28 billion, bone graft products of KRW 26.7 billion, medical devices (lifting threads and hair transplant devices) of KRW 28.5 billion and other products (breast implants, scar treatments and others) of KRW 6.6 billion.

Domestic sales of KRW 70.7 billion in the nine-month period rose 73% year on year, and exports of KRW 30.4 billion rose 21%. The BOUNS silicone breast implant, launched in Korea in April 2026, is expanding its supplier base mainly among plastic surgery clinics. In China, the company is preparing local production through a joint venture called Revos.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q2₩22B₩40,796,5590.2%
2025Q3₩23.7B-₩27B−113.6%
2025Q4₩30.3B₩2.1B6.8%
2026Q1₩34.5B₩4.4B12.9%
2026Q2₩36.3B₩4.1B11.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023.09₩78B-₩4.2B-₩23B−5.3%−46.9%145.0%
2024.09₩81.1B₩600M-₩7.2B0.8%−10.8%81.3%
2025.09₩89.8B-₩25.9B-₩31.3B−28.8%−93.0%273.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue went from KRW 78 billion in the year ended September 2023 to KRW 81.1 billion in the year ended September 2024 (up 4.0%) and KRW 89.8 billion in the year ended September 2025 (up 10.7%), rising for two consecutive years from the year ended September 2024 through the year ended September 2025, with the year ended September 2025 the largest of the three.

Operating results moved from an operating loss of KRW 4.15 billion in the year ended September 2023 to operating profit of KRW 626 million in the year ended September 2024 (a turn to profit from a year earlier) and an operating loss of KRW 25.9 billion in the year ended September 2025 (a turn back to a loss), with operating margins of -5.3%, 0.8% and -28.8%.

Net loss attributable to controlling shareholders was KRW 23 billion, KRW 7.22 billion and KRW 31.3 billion across the three years, a continuing loss that narrowed in 2024 and widened in 2025.

Total net loss including non-controlling interests was KRW 32.1 billion in the year ended September 2025, against KRW 7.8 billion a year earlier.

Business reports show selling, general and administrative expenses rose to KRW 77.4 billion in the year ended September 2025 from KRW 51.1 billion, while cost of sales rose to KRW 38.2 billion from KRW 29.3 billion, and a May 2026 securities report said litigation costs and delayed normalization had weighed on profitability.

The debt ratio was 145.0%, 81.3% and 273.0% across the three years; at the end of September 2025, total equity stood at KRW 33.9 billion, of which KRW 33.7 billion belonged to controlling shareholders, against total liabilities of KRW 92.5 billion.

Operating cash flow was -KRW 3.73 billion, KRW 1.76 billion and KRW 318 million across the three years.

Quarterly revenue rose from KRW 23.7 billion in the third quarter of 2025 to KRW 30.3 billion in the fourth quarter (up 27.6% quarter on quarter), KRW 34.5 billion in the first quarter of 2026 (up 13.9%) and KRW 36.3 billion in the second quarter (up 5.4%), and the second quarter of 2026 was up 65.0% year on year.

Operating profit moved from an operating loss of KRW 27 billion in the third quarter of 2025 to KRW 2.06 billion in the fourth quarter (a turn to profit), KRW 4.44 billion in the first quarter of 2026 (up 115.1%) and KRW 4.1 billion in the second quarter (down 7.7%), with the second-quarter decline tied to higher marketing spending.

Net profit attributable to controlling shareholders went from a loss of KRW 27.6 billion in the third quarter of 2025 to KRW 2.06 billion in the fourth quarter, KRW 3.96 billion in the first quarter of 2026 (up 92.9%) and KRW 1.93 billion in the second quarter (down 51.3%), and the last four quarters total a net loss attributable to controlling shareholders of KRW 19.7 billion.

The cumulative operating margin for the first three quarters of fiscal 2026 (October 2025 to June 2026) was 10.5%, up from 1.6% a year earlier, and the selling expense ratio fell to 52.9% from 60.4%.

Full-year results for the year ending September 2026 have not yet been filed, so whether the quarterly recovery holds on an annual basis remains to be confirmed.

05

Industry analysis

Within domestic human-tissue-based implant materials, ECM skin boosters are in a phase of rapid growth.

A Yuanta Securities report describes Hans Biomed as the first company in Asia to commercialize human skin, bone and silicone implant products and as the holder of Korea's first human tissue bank establishment license.

CellREDM is drawing attention in the skin booster market on the strength of the homogeneity and biocompatibility of its ECM-based composition, and its customer count had grown to more than 600 clinics as of May 2026.

An Edaily report estimated the Chinese human tissue implant market at KRW 4 trillion to 6 trillion, or 20 to 30 times the Korean market of about KRW 200 billion. The same report put the Chinese bone graft market at more than KRW 500 billion, more than five times the Korean bone graft market of about KRW 100 billion.

It also argued that after the only other major competitor in Chinese bone graft halted production over illegal raw material use, the company could in practice sell with little competition. In China, sales run through two routes: local production via Revos and direct exports.

At the time, a company official said Revos's regulatory approval was delayed by a nationwide raw material inspection. The skin booster market includes several domestic players, including PharmaResearch, so competition for share is intense.

The Hugel collaboration began in July 2026, and the company presents it as an additional growth driver for CellREDM.

06

Outlook

The next checkpoint is the full-year results for the year ending September 2026, which an investment information site lists for December 17, 2026. In a report at the end of September 2026, the Korea IR Association projected that revenue would rise 52.9% this year and that operating profit would turn to a profit.

Beyond the two products, the company presents overseas regulatory approvals as a growth driver. Singapore approval has been obtained, and expansion into Japan has begun as the first step in broader overseas markets.

A late-2025 report said CellREDM production capacity would expand from about 15,000 units a month at the end of 2025 to more than 40,000 units in early 2026.

The company's near-term goal for BOUNS is to build it into a product generating KRW 10 billion a year, and it has announced plans to expand to more than 100 plastic surgery clinics within the calendar year 2026. In May 2026, Sangsangin Securities projected bone graft export sales to China at KRW 3 billion for the year.

Local production through a joint venture and investment in a regenerative osteoarthritis therapy are proceeding in parallel. The next items to watch are whether CellREDM and BOUNS raise their share of revenue and whether the operating margin holds at around the low double digits.

07

Valuation

PER
—
PBR
—
ROE
-27.9%
EPS
-₩1,557
BPS
—
Dividend per share
₩0

The last four quarters total a net loss attributable to controlling shareholders of KRW 19.7 billion, so the price-to-earnings ratio cannot be calculated. Profit has been positive only since the fourth quarter of 2025, so the earnings base for a multiple is still short. The dividend yield is below the industry average.

Market capitalization is several times the equity attributable to controlling shareholders at the end of September 2025, which places the stock at a large premium to book value.

The operating margin moved from -5.3% in the year ended September 2023 to -28.8% in the year ended September 2025, and has returned to positive territory on a quarterly basis during 2026. Because the profit base is short, comparison of multiples with listed peers is limited for now.

Once the full-year results for the year ending September 2026 are filed, whether a multiple can be calculated and the period used for interpretation will both change.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Skin graft and CellREDM growth

In the first three quarters of fiscal 2026 (October 2025 to June 2026), skin graft revenue reached KRW 48.5 billion, up 157% year on year, and its share of total revenue rose to 48%.

CellREDM's third-quarter sales were KRW 7.2 billion, up 62% from the prior quarter, and its customer base had grown to more than 600 clinics as of May 2026. The company said CellREDM, BellaCellHD and BellaGen Plus all grew sharply.

Recovery in earnings structure

Operating profit in the second quarter of 2026 was KRW 4.1 billion, and profitability has held since the operating loss of KRW 27 billion in the third quarter of 2025. According to the company, the cumulative operating margin for fiscal 2026's first three quarters rose to 10.5% from 1.6% a year earlier.

The selling expense ratio fell to 52.9% from 60.4%, as revenue growth outpaced growth in selling and administrative costs.

Overseas and new product expansion

The company obtained Singapore approval and has begun expansion into Japan. Exports of orthopedic bone graft products to China started in January 2026 and generated KRW 1 billion in the January to March 2026 quarter.

BOUNS, launched in April 2026, is expanding its supplier base mainly among plastic surgery clinics, with a target of more than 100 clinics within the year.

09

Bear factors

Loss history and balance sheet strain

The year ended September 2025 posted an operating loss of KRW 25.9 billion and a net loss attributable to controlling shareholders of KRW 31.3 billion, a third straight year of losses. The debt ratio rose to 273.0% at the end of September 2025 from 81.3% a year earlier, and total equity was KRW 33.9 billion.

The last four quarters' net loss attributable to controlling shareholders of KRW 19.7 billion largely reflects the KRW 27.6 billion loss in the third quarter of 2025.

Residual BellaGel litigation risk

The company paid about KRW 22 billion, roughly KRW 4 million per person, to about 5,300 participants in the first BellaGel lawsuit. A Sangsangin Securities report said the possibility of additional lawsuits remains an uncertainty.

Reports also said the company did not appeal after losing at first instance, so changes in litigation costs and provisions could affect the earnings trend.

Marketing and selling expense burden

Operating profit in the second quarter of 2026 fell 7.7% from the prior quarter, which the company attributed to higher domestic and overseas marketing costs. Selling, general and administrative expenses in the year ended September 2025 rose to KRW 77.4 billion, up KRW 26.3 billion from a year earlier.

Even with revenue growth, a heavier expense load could constrain margins, so the trend in operating margin is an important variable.

10

Risk factors

Litigation risk

Compensation from the first BellaGel lawsuit was paid in November 2025, but whether further suits will be filed and their size remain undetermined. Additional provisions or costs could again pressure operating profit and net profit attributable to controlling shareholders. The effect of such costs is larger given the company's high debt ratio.

Product concentration risk

Skin graft products account for 48% of cumulative revenue in the first three quarters of fiscal 2026, and CellREDM's share of quarterly revenue has risen to 20%. When growth depends on a few product lines, competing launches or regulatory changes have a larger effect on results. A Sangsangin Securities report from April 2026 noted that BOUNS production yields were low in the early stage.

Overseas expansion and approval risk

Overseas revenue depends on approval progress in markets such as Japan and Singapore, and China approvals are still in process. Revos's approval was delayed by a nationwide raw material inspection in the past.

Late 2025 also saw the company decide to liquidate its UK, Irish and Thai subsidiaries as part of a restructuring.

11

What to watch next

  1. December 17, 2026

    This is the scheduled date for the annual earnings release for the fiscal year ending September 2026 (based on the schedule of an investment information site). The points to check are whether the 10.5% cumulative operating margin through the third quarter holds for the full year, and how the SG&A ratio and Selreudiem's share of sales have moved.

  2. Late December 2026

    This falls around the filing deadline for the annual report for the fiscal year ending September. The point to check is whether the report covers the notes on litigation provisions and contingent liabilities, the results of liquidating overseas subsidiaries, and the progress of licensing and approval for Revos in China.

  3. Within 2026

    This is whether the target of 100 or more plastic surgery clinics as Bounce supply accounts is achieved. Another point to check is how far Bounce sales reach against the target of building it into a business worth 10 billion won a year.

12

Overall view

Hans Biomed's Q2 2026 results showed a profit trend, with revenue of KRW 36.3 billion and operating profit of KRW 4.1 billion, driven by growth in CellREDM and skin graft products.

The year ended September 2025 saw losses widen to an operating loss of KRW 25.9 billion and a net loss attributable to controlling shareholders of KRW 31.3 billion, so whether the quarterly recovery carries through to a full year must be checked against the results for the year ending September 2026.

Factors supporting the outlook include four consecutive quarters of revenue growth, a 48% share from skin graft products, a lower selling expense ratio and progress on overseas approvals.

Factors weighing on it include three straight years of losses, a debt ratio that rose to 273.0%, the possibility of further BellaGel lawsuits, and lower operating profit in Q2 2026 from higher marketing costs.

The last four quarters' net loss attributable to controlling shareholders of KRW 19.7 billion leaves the price-to-earnings ratio uncalculated. The next points to track are whether the revenue share of BOUNS and CellREDM grows and whether the operating margin holds.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. hansbiomed.com
  2. medipana.com
  3. hansbiomed.com
  4. hankyung.com
  5. buffettlab.co.kr
  6. pharm.edaily.co.kr
  7. pharm.edaily.co.kr
  8. m.news.nate.com
  9. news.nate.com
  10. newspim.com
  11. comp.fnguide.com
  12. news.nate.com
  13. investing.com
  14. hankyung.com
  15. investing.com
  16. file.alphasquare.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis